Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2739 | NT-I7 Wiki | 1.00 |
drug650 | Blood for pharmacokinetic samples Wiki | 1.00 |
drug651 | Blood for research purposes Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Generalized anxiety disorder (GAD) is a debilitating condition involving excessive and uncontrollable worry and anxiety. Difficulty tolerating the uncertainties of life, known as intolerance of uncertainty (IU), has been shown to be key in the development and maintenance of GAD symptoms. A new, streamlined cognitive-behavioural treatment that targets IU has been shown to be effective in at reducing GAD symptoms, IU, and general psychopathology when delivered one-on-one with a therapist, as shown in a recently published pilot study. The individual format of this treatment is now being evaluated in a randomized controlled trial (RCT). The overall objective of this study is to pilot test a group version of the treatment protocol to determine if a future RCT of this group treatment is both warranted and feasible. We will also conduct a preliminary investigation into the group treatment's efficacy. A total of two pilot groups (N = 12-20) will be conducted via two clinical hospital sites in Winnipeg, Manitoba, Canada. The group treatment protocol will be delivered over the course of 12 weekly therapy sessions. Participants will complete assessment measures at pretreatment, posttreatment, and at a 6-month follow-up point. All assessments and treatment sessions will be conducted virtually via videoconferencing platform due to ongoing COVID-19 pandemic restrictions.
Description: Diagnostic status as measured by the MINI (Sheehan et al., 1994). Clinical Severity Rating adapted from the ADIS, with scores ranging from 0-8 (higher scores indicating greater GAD severity)
Measure: MINI International Neuropsychiatric Interview Time: Pretreatment (prior to the intervention).Description: Diagnostic status as measured by the MINI (Sheehan et al., 1994).Clinical Severity Rating adapted from the ADIS, with scores ranging from 0-8 (higher scores indicating greater GAD severity)
Measure: MINI International Neuropsychiatric Interview Time: Posttreatment (after completing final session of the treatment intervention)Description: Diagnostic status as measured by the MINI (Sheehan et al., 1994). Clinical Severity Rating adapted from the ADIS, with scores ranging from 0-8 (higher scores indicating greater GAD severity)
Measure: MINI International Neuropsychiatric Interview Time: 6-month follow-upDescription: Self-reported GAD symptoms as measured by the WAQ (Dugas et al., 2001). Scores range from 0-80 with higher scores indicating higher GAD severity.
Measure: Worry and Anxiety Questionnaire Time: Pretreatment (prior to the intervention).Description: Self-reported GAD symptoms as measured by the WAQ (Dugas et al., 2001). Scores range from 0-80 with higher scores indicating higher GAD severity.
Measure: Worry and Anxiety Questionnaire Time: Posttreatment (after completing final session of the treatment intervention)Description: Self-reported GAD symptoms as measured by the WAQ (Dugas et al., 2001). Scores range from 0-80 with higher scores indicating higher GAD severity.
Measure: Worry and Anxiety Questionnaire Time: 6-month follow-upDescription: Self-reported difficulties tolerating uncertainty (Freeston, Rhéaume, et al., 1994). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty.
Measure: Intolerance of Uncertainty Scale Time: Pretreatment (prior to the intervention).Description: Self-reported difficulties tolerating uncertainty (Freeston, Rhéaume, et al., 1994). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty.
Measure: Intolerance of Uncertainty Scale Time: Posttreatment (after completing final session of the treatment intervention)Description: Self-reported difficulties tolerating uncertainty (Freeston, Rhéaume, et al., 1994). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty.
Measure: Intolerance of Uncertainty Scale Time: 6-month follow-upDescription: A measure of self-reported depression, anxiety, and stress symptoms (Lovibond & Lovibond, 1995). Higher scores on a subscale indicate greater severity in that symptom area (i.e., depression, anxiety, or stress, respectively).
Measure: Depression Anxiety Stress Scales Time: Pretreatment (prior to the intervention).Description: A measure of self-reported depression, anxiety, and stress symptoms (Lovibond & Lovibond, 1995). Higher scores on a subscale indicate greater severity in that symptom area (i.e., depression, anxiety, or stress, respectively).
Measure: Depression Anxiety Stress Scales Time: Posttreatment (after completing final session of the treatment intervention)Description: A measure of self-reported depression, anxiety, and stress symptoms (Lovibond & Lovibond, 1995). Higher scores on a subscale indicate greater severity in that symptom area (i.e., depression, anxiety, or stress, respectively).
Measure: Depression Anxiety Stress Scales Time: 6-month follow-upDescription: A measure of self-reported excessive worry (Meyer, Miller, Metzger, & Borkovec, 1990). Scores range from 16-80 with higher scores indicating greater worry severity.
Measure: Penn State Worry Questionnaire Time: Pretreatment (prior to the intervention).Description: A measure of self-reported excessive worry (Meyer, Miller, Metzger, & Borkovec, 1990). Scores range from 16-80 with higher scores indicating greater worry severity.
Measure: Penn State Worry Questionnaire Time: Posttreatment (after completing final session of the treatment intervention)Description: A measure of self-reported excessive worry (Meyer, Miller, Metzger, & Borkovec, 1990). Scores range from 16-80 with higher scores indicating greater worry severity.
Measure: Penn State Worry Questionnaire Time: 6-month follow-upDescription: Self-reported tendency toward 5 dimensions of curiosity (Kashdan et al., 2018), with higher scores on each respective subscale indicating greater tendency toward a specific facet of curiousity.
Measure: Five Dimensional Curiosity Scale Time: Pretreatment (prior to the intervention).Description: Self-reported tendency toward 5 dimensions of curiosity (Kashdan et al., 2018), with higher scores on each respective subscale indicating greater tendency toward a specific facet of curiousity.
Measure: Five Dimensional Curiosity Scale Time: Posttreatment (after completing final session of the treatment intervention)Description: Self-reported tendency toward 5 dimensions of curiosity (Kashdan et al., 2018), with higher scores on each respective subscale indicating greater tendency toward a specific facet of curiousity.
Measure: Five Dimensional Curiosity Scale Time: 6-month follow-upDescription: Self-reported quality of life (Endicott, Nee, Harrison, & Bulmental, 1993), with scores ranging from 14-70 (higher scores indicating greater overall quality of life).
Measure: Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form Time: Pretreatment (prior to the intervention).Description: Self-reported quality of life (Endicott, Nee, Harrison, & Bulmental, 1993), with scores ranging from 14-70 (higher scores indicating greater overall quality of life).
Measure: Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form Time: Posttreatment (after completing final session of the treatment intervention)Description: Self-reported quality of life (Endicott, Nee, Harrison, & Bulmental, 1993), with scores ranging from 14-70 (higher scores indicating greater overall quality of life).
Measure: Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form Time: 6-month follow-upDescription: Self-report measure of the participant's perception of the treatment's acceptability and their anticipated adherence to the intervention (Milosevic, Levy, Alcolado, & Radomsky, 2015). Scores range from 10 to 70 with greater scores indicating greater treatment acceptability and anticipated adherence.
Measure: Treatment Acceptability/Adherence Scale Time: MidtreatmentDescription: Self-reported tendency to use safety behaviours to manage anxiety (Hebert & Dugas, 2019). Scores range from 18 to 90 with higher scores indicating greater use of safety behaviours.
Measure: GAD Safety Behaviours Questionnaire Time: Pretreatment (prior to the intervention).Description: Self-reported tendency to use safety behaviours to manage anxiety (Hebert & Dugas, 2019). Scores range from 18 to 90 with higher scores indicating greater use of safety behaviours.
Measure: GAD Safety Behaviours Questionnaire Time: Posttreatment (after completing final session of the treatment intervention)Description: Self-reported tendency to use safety behaviours to manage anxiety (Hebert & Dugas, 2019). Scores range from 18 to 90 with higher scores indicating greater use of safety behaviours.
Measure: GAD Safety Behaviours Questionnaire Time: 6-month follow-upDescription: Self-report measure assessing intolerance of uncertainty in the past week (Dugas, 2008). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty in the past week.
Measure: IUS Past-Week Time: Weekly from session 1 to session 12 of treatmentDescription: Self-report measure of the tendency to worry excessively in the past week (Stöber, J., & Bittencourt, J., 1998). Scores range from 3 to 15 with greater scores indicating greater tendency to worry excessively in the past week.
Measure: Penn State Worry Questionnaire Past-Week Time: Weekly from session 1 to session 12 of treatmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports